Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 11/20 | 0.54 |
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CTSV | O60911 | 1/20 | 0.36 |
| ▸ | PLAT | P00750 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSH | P09668 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CASP14 | P31944 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | CTSZ | Q9UBR2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27754039 | 0.88 | CSNK2A1 (0.61) | CSNK2A1CSNK2A2CDK1 | |
| SCHEMBL4114317 | 0.85 | CSNK2A1 (0.60) | CSNK2A1 | |
| SCHEMBL3996659 | 0.83 | CSNK2A1 (0.60) | CSNK2A1 | |
| SCHEMBL4107150 | 0.80 | KDM4E (0.47) | CSNK2A1 | |
| SCHEMBL13650619 | 0.78 | CSNK2A1 (0.73) | CSNK2A1CDK1 | |
| SCHEMBL4119289 | 0.73 | CSNK2A1 (0.34) | CSNK2A1CSNK2A2CTSSCTSK | |
| Benzene SCHEMBL4492595 | 0.73 | CSNK2A1 (0.36) | CSNK2A1CSNK2A2 | |
| SCHEMBL4114828 | 0.72 | CSNK2A1 (0.51) | CSNK2A1 | |
| SCHEMBL4111581 | 0.71 | CSNK2A1 (0.35) | CSNK2A1CSNK2A2CTSSCTSK | |
| SCHEMBL20549637 | 0.70 | CSNK2A1 (0.57) | CSNK2A1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101522683-B | Pyrazolo (1,5-A) (1,3,5) triazine and pyrazolo (1,5-A) pyrimidine derivatives useful as protein kinase inhibitors | POLARIS GROUP | 2013-02-27 | — | — | CN | disclosed |
| EP-2064214-B1 | Pyrazolo[l,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives useful as protein kinase inhibitors | POLARIS GROUP (TW) | 2013-01-30 | — | — | EP | disclosed |
| US-20090247501-A1 | PROTEIN KINASE INHIBITORS | POLARIS GROUP (TW) | 2009-10-01 | — | — | US | disclosed |
| US-20090247501-A1 | PROTEIN KINASE INHIBITORS | POLARIS GROUP (TW) | 2009-10-01 | — | — | US | disclosed |
| US-20090247501-A1 | PROTEIN KINASE INHIBITORS | POLARIS GROUP (TW) | 2009-10-01 | — | — | US | disclosed |
| US-7517882-B2 | Protein kinase inhibitors | POLARIS GROUP (CN) | 2009-04-14 | — | — | US | disclosed |
| US-7517882-B2 | Protein kinase inhibitors | POLARIS GROUP (CN) | 2009-04-14 | — | — | US | disclosed |
| US-7517882-B2 | Protein kinase inhibitors | POLARIS GROUP (CN) | 2009-04-14 | — | — | US | disclosed |
| US-20080070893-A1 | Protein Kinase Inhibitors | POLARIS GROUP (CN) | 2008-03-20 | — | — | US | disclosed |
| US-20080070893-A1 | Protein Kinase Inhibitors | POLARIS GROUP (CN) | 2008-03-20 | — | — | US | disclosed |
| US-20080070893-A1 | Protein Kinase Inhibitors | POLARIS GROUP (CN) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070893-A1 | Protein Kinase Inhibitors | MAP3K15, MAP3K20, MAP3K5 | CSNK2A1 482/4885CSNK2A2 441/4885CDK1 71/4885 |
| US-20090247501-A1 | PROTEIN KINASE INHIBITORS | MAP3K15, MAP3K20, MAP3K5 | CSNK2A1 482/4885CSNK2A2 441/4885CDK1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.